Therapy Area
Regenxbio earns key FDA designation for DMD gene therapy
Regenxbio’s gene therapy RGX-202 gains an important regulatory marker as it looks to compete in a crowded field of DMD therapies.
Hansa starts dosing in Phase III trial in anti-GBM disease
Immutep selects Charles River to conduct toxicology study for IMP761
Alzinova doses first patient in extension part of Phase Ib ALZ-101 trial
Alterity initiates new Phase II advanced MSA therapy trial
Pipeline Moves: Novo Nordisk Phase III semaglutide completion bumps approval prospects
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
